Mavens Biotech Ltd Directors Report

Dear Members

The Board of Directors are pleased to present the 42^nd Annual Report together with the Audited Financial Statement of Accounts and Auditors Report of the Company for the year ended 31^st March, 2024 along with the Auditors Report thereon.

The financial highlights of the Company for F.Y. 2023-2024 are given below:

(Amt. in Lakhs)

Particulars	31st March, 2024	31st March, 2023
Total Income	9.62	0.18
Less: Expenses	16.31	17.14
Less: Exceptional Items	(10.80)	(18.81)
Profit/ -Loss before Taxation	4.11	1.85
Less: Taxation	-	-
Profit after Taxation	4.11	1.85

Performance

The Total Income for the financial year under review is Rs. 9.62 Lakh against Rs. 0.18 Lakh in previous year. The Net Profit after taxation marked by the company during the year under review was Rs. 4.11 Lakh as compared to profit of Rs. 1.85 Lakh during the previous year.

Compliance with the Indian Accounting Standards

As mandated by the Ministry of Corporate Affairs, the financial statements for the year ended on March 31, 2024 has been prepared in accordance with the Indian Accounting Standards (IND AS) notified under Section 133 of the Companies Act, 2013 read with the Rule 7 of Companies (Accounts) Rules, 2014.

Operation

The Company has been continuously focusing on its existing line of business to improve its profitability in near future.

Dividend and Transfer to Reserve

Your Company intends to conserve available resources to invest in the growth of the business and pursue strategic growth opportunities. Accordingly, your Directors do not recommend any dividend for the year. There has been no transfer to Reserves during the Financial Year 2023-2024.

Change in the Nature of Business

There is no change in the nature of business of the Company during the year under review.

Public Deposits

The Company has not accepted or renewed any amount falling within the purview of provisions of section 73 and 74 of the Companies Act, 2013 read with the Companies (Acceptance of Deposit) Rules, 2014 during the year under review. Hence, the requirement for furnishing of details of deposits is not applicable.

Directors and Key Managerial Personnel (KMP)

As on March 31, 2024, the Board of Directors of your Company comprised of Four (4) Directors one (1) of them Whole time Director and other three (Rs) are Non-Executive Independent directors including one Women director.

The composition of the Board is in consonance with Regulation 17 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and in accordance with the applicable provisions of Companies Act, 2013.

As reported last year, Mr. Biswajit Barua (DIN: 06992250), was appointed as an Additional and Non-Executive Independent Director on the Board of the Company w.e.f. July 26, 2023. At the 41^st AGM held on September 11, 2023, the Members approved her appointment as an Independent Director of the Company for a period of 5 years i.e., from July 26, 2023 to July 25, 2028.

Mr. Kishan Singh (DIN: 07526266), has tendered his resignation due to personal and unavoidable circumstances, letter dated 22/07/2023 to the board from the post of Non-executive Independent Director. There is no material reason for their resignation from the Company other than mentioned above. The Board has considered and approved her resignation in their meeting held on 26/07/2023 after conclusion of Board Meeting of the Company. The Board places on record its gratitude for the services rendered by her during the tenure as Whole Time Director of the Company.

Mr. Ganga Sahai was resigned from the post of Chief Financial Officer (CFO) w.e.f. 04/08/2023.

Mr. Abhishek Kumar Jain was appointed as Chief Financial Officer (CFO) of the Company on 04/08/2023.

Board approved in their meeting held on 27/05/2024 along with recommendation of Nomination & Remuneration Committee of Board that Change in Designation of Mr. Jay Prakash (DIN: 02525414) from Whole time Director to Managing Director & Chief Executive Officer with immediate effect on the existing terms & conditions. Accordingly he will hold office as Managing Director and Chief Executive Officer for his remaining tenure of his office viz. upto 27/01/2027. However there is no change in his existing remuneration. The change in designation is being carried out for re-organizing the Board. The Board has also decided to carry out 42^nd Annual General Meeting for availing approval of Shareholders to above change.

Mrs. Sunita Hanuman Singhi (DIN: 06992243) has been appointed as Additional Director w.e.f. June 26, 2024 and being act as Independent Directors, in category as Non-executive Independent Director for consecutive 5 (Five) years for the period from 26/06/2024 to 25/06/2029 and in terms Listing Regulation 16 & any other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 149 of the Companies Act, 2013. The resolutions seeking approval of members on item No. 3 of notice for convening the Annual General Meeting along with the requisite disclosures/explanatory statement are included.

All Independent directors have given the Declarations that they meet the criteria of Independence as laid down under Section 149(6) of the Companies Act, 2013, and Clause 16(b) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. In the opinion of the Board, all the Independent Directors are persons of integrity, and possess expertise and experience including the proficiency required to be Independent Directors of the Company and they are independent of the management and have also complied with the Code for Independent Directors as prescribed in Schedule IV of the said Act.

All Independent Directors of the Company have confirmed that they have already registered their names with the data bank maintained by the Indian Institute of Corporate Affairs ["IICA"] as prescribed by the Ministry of Corporate Affairs under the relevant Rules, and that they would give the online proficiency self-assessment test conducted by IICA which is prescribed under the relevant Rules, if applicable.

Appropriate resolutions for appointment/ re-appointment are being placed for the approval of the shareholders of the Company at the ensuing AGM. The brief resume of directors appointed/re- appointed and other related information has been detailed in the Notice read along with the explanatory statement convening the 42^nd AGM of the Company in accordance with the provisions of the Companies Act, 2013 read with the Rules issued there under and the Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Disclosure under Section 197(12) of the Companies Act, 2013

The Company has not employed any employees whose remuneration falls within the purview of the limits prescribed under the provisions of Section 197 of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Policy on Directors Key Managerial Personnel -Appointment & Remuneration including Nomination & Remuneration Committee

The Board has framed a policy on Directors Appointment and Remuneration & duly constituted Nomination and Remuneration Committee pursuant to Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 and read with Section 178 of the Companies Act, 2013.

The policy provides for selection and appointment of Directors, Senior Management including KMP and their Remuneration together with criteria for determining qualifications, positive attributes, and independence of a Director.

Remuneration policy for the Directors, Key Managerial Personnel and other Employees has been disclosed on the Company website i.e. https://www.mavensbiotech.com/SEBI-LODR.html.

Details of Committee members and meetings etc. have been disclosed in the Corporate Governance Report which forms a part of this report.

Directors Responsibility Statement

Pursuant to Section 134 (Rs) (c) read with Section 134 (5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:

i. in the preparation of the annual accounts for the year ended 31^st March, 2024, the applicable Indian Accounting Standards have been followed along with proper explanation relating to material departures, if any; ii. the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 31^st March, 2024 and of the profit or loss of the company for the year ended on that date; iii. the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities; iv. the annual accounts have been prepared on a going concern basis; v. the directors have laid down internal financial controls to be followed by the company and such internal financial controls are adequate and operating effectively; vi. the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Declaration of Independent Directors

The Company has received necessary declaration from each of Independent Directors under Section 149(7) of the Companies Act, 2013, that they meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and the relevant Rules made there on and Regulation 16(1)(b) and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

All Independent Directors of the Company have submitted the requisite declarations confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Act read with Regulation 16 and 25(8) of SEBI Listing Regulations. The Independent Directors have also confirmed that they have complied with Schedule IV of the Act and the Companys Code of Conduct. In the opinion of the Board, all the independent directors are persons of integrity, possesses relevant expertise and experience including the proficiency required to be

Independent Directors of the Company and they are independent of the management and have also complied with the Code for Independent Directors as prescribed in Schedule IV of the said Act..

All Independent Directors of the Company have confirmed that they have already registered their names with the data bank maintained by the Indian Institute of Corporate Affairs ["IICA"] as prescribed by the Ministry of Corporate Affairs under the relevant Rules, and that they would give the online proficiency self-assessment test conducted by IICA which is prescribed under the relevant Rules, if applicable.

Committee of the Board:

The Board of Directors has following Committee

a. Audit Committee b. Nomination & Remuneration Committee c. Stakeholder Relationship Committee d. Risk Management Committee

The details of the Committees along with their composition, number of meetings and attendance at the meetings are provided in the Corporate Governance Report.

Statement concerning development and implementation of Risk Management Policy of the Company

The Board of Directors of the Company has constituted a Risk Management Committee to frame, implement and monitor the risk management plan for the Company. The Committee is responsible for reviewing the risk management plan and ensuring its effectiveness. The Committee has additional oversight in the area of financial risks and controls. Major risks identified by the business and functions are systematically address through mitigation action on a continuing basis. The details of Committee and its terms of reference are set out in the Corporate Governance Report forming part of the Board Report.

Number of Meeting of the Board

During the year under review 5 (Five) Meetings of the Board of Directors were held. The relevant details including composition of the Board, date of meetings, attendance and composition of various Committees of the Board are given in the Corporate Governance Report which forms part of this report. The details regarding the composition of various committees are also available on the Companys website: www.mavensbiotech.com.

Disclosure regarding Companys policies under Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Company has framed various policies as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 & Companies Act, 2013; viz i) Remuneration Policy for the Directors , Key Managerial Personnel and other Employees ii) Determining material Events Policy iii) Policy on Related Party transactions, iv) Whistle Blower/vigil Mechanism v) Archival Policy for disclosure vi) Code of Conduct for Directors & Senior Management vii) Policy of Preservation of Documents viii) Policy for Determining Materiality subsidiary ix) Code of Conduct for Independent Director are displayed on the website of the Company https://www.mavensbiotech.com/SEBI-LODR.html.

Subsidiaries, Joint Ventures and Associate Companies

The Company does not have any Subsidiary, Joint venture or Associate Company.

Extract of Annual Return

Pursuant to the provisions of Section 92(Rs) and Section 134(Rs) (a) of the Companies Act, 2013 read with Rule 12(1) of the Companies (Management and administration) Rules, 2014, the Annual Return as on 31^st March, 2024 is available on the Companys website www.mavensbiotech.com.

Board Evaluation

Pursuant to the provisions of the Companies Act, 2013 and Listing Regulations 17 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the Board has carried out an Annual Performance evaluation of its own performance, the Directors individually as well as the evaluation of the working of its various Committees.

A separate exercise was carried out to evaluate the performance of individual Directors including the Chairman of the Board, who were evaluated on parameters such as level of engagement and contribution, independence of judgment, safeguarding the interest of the Company and its minority shareholders etc.

The performance evaluation of the Independent Directors was carried out by the entire Board excluding the Directors being evaluated.

The Performance evaluation of the Chairman and Non-Independent Directors was carried out by the Independent Directors at their separate Meeting.

The Board of Directors expressed its satisfaction with the evaluation process.

Particulars of Loans, Guarantees or Investments made under Section 186 of the Companies Act, 2013

The Company has complied with the provisions of Section 186 of the Companies Act, 2013 in respect of investments made and outstanding at the year-end, details of which are given in the Financial Statements. There were no loans or guarantees made by the Company during the year under review.

Particulars of Contracts or Arrangements made with Related Parties

During the Financial Year 2023-2024, all contracts/ arrangements/ transactions entered into by your Company with related parties under Section 188(1) of the Companies Act, 2013 and Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 were in the ordinary course of business and at arms length basis. Your Company has not entered into any contracts /arrangements /transactions with related parties which could be considered ‘material. Thus, there are no transactions required to be reported in form AOC-2 under Section 134(Rs) of the Companies Act. There were no materially significant related party transactions made by your Company with the Promoters, Directors, Key Managerial Personnel or other designated persons, which might have potential conflict with the interest of the Company at large. The Company has developed a Related Party Transactions Policy for the purpose of identification and monitoring of such type of transactions. Attention of the members is drawn to the disclosures of transactions with the related parties is set out in Notes to Accounts forming part of the financial statement for the year 2023-2024.

Internal Financial Control and their adequacy

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The Company has developed well-defined internal control mechanisms and comprehensive internal audit program with the activities of the entire organization under its ambit. Further, based on the report of Internal Audit function, corrective action are undertaken in the respective areas and thereby strengthen the controls. Significant audit observations and corrective actions thereon are presented to the Audit Committee of the Board.

During the year under review, no material or serious observation has been received from the Internal Auditors of the Company for inefficiency or inadequacy of such controls.

Corporate Governance

The Company conforms to the norms of Corporate Governance as envisaged in the Listing Regulations with the Stock Exchange. Pursuant to Regulation 34(Rs) read with Schedule V of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, and a detailed Compliance Note on Corporate Governance together with the Auditors Certificate on Corporate Governance is annexed to this report.

Management Discussion and Analysis Report

The Management Discussion and Analysis Report for the year under review, as stipulated under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") are given in a separate section and forms part of the Annual Report.

Material Changes and Commitments, if any, affecting the financial position of the Company occurred between the ends of the financial year to which this financial statement relates and the date of the report

There are no material changes and commitments affecting the financial position of the Company occurred between ends of the financial year to which this financial statement relates on the date of this report.

The details of difference between amount of the valuation done at the time of one time settlement and the valuation done while taking loan from the banks or financial institutions along with the reasons thereof:

Not Applicable to the Company during the year under review.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The statement of particulars under Section 134(Rs) (m) of the Companies Act, 2013 read with Rule 8(Rs) of the Companies (Accounts), 2014 regarding conservation of energy, technology absorption and Foreign Exchange earnings and outgo are given below:

3 Your Company has not consumed energy of any significant level. Accordingly, no measures were taken for energy conservation and no investment is required to be for reduction of energy consumption.

3 No comment is made on technology absorption, considering the nature of activities undertaken by your Company during the year under review.

3 No Expenditure has been made for research and development during the year under review.

3 There were no Foreign Exchange earnings or out go during the year under review.

Details of significant and material orders passed by the Regulators or Courts or Tribunals impacting the Going Concern status and Companys operation in future

There are no significant and material orders issued against the Company by any regulating authority or court or tribunal affecting the going concern status and Companys operation in future. Hence, disclosure pursuant to Rule 8 (5) (vii) of Companies (Accounts) Rules, 2014 is not required.

Auditors & Auditors Observations

The matter related to Auditors and their Reports are as under:

1. Statutory Auditor and their Report:

As per the requirements of Section 139(2) of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014, the Board of Directors in the meeting held on 26^th July, 2023 and on the recommendation of the Audit Committee, the appointment of M/S. Mohindra Arora & Co., Chartered Accountant (FRN No. 006551N) as the Statutory Auditors of the Company for a period of five years from the conclusion of the 41st Annual General Meeting (AGM) till the conclusion of 46^th AGM approved by the members at 41st Annual General Meeting.

Statutory Auditor have confirmed that they are not disqualified from continuing as Auditors of the Company. The requirement to place the matter relating to appointment of Auditors for ratification by members at every AGM is done away with vide notification dated 7^th May, 2018 issued by the Ministry of Corporate Affairs, New Delhi.

Explanations or Comments on Qualifications, Reservations or Adverse Remarks or Disclaimers made by the Statutory Auditors in their Report:

The Report given by M/S. Mohindra Arora & Co., Chartered Accountant (FRN No. 006551N), Statutory Auditors of the Company for the Financial Statements for the year ended 31^st March, 2024 read with explanatory notes thereon do not call for any explanation or comments from the Board under Section 134(Rs) of the Companies Act, 2013. The remarks, if any, made by the Auditors in their Report are properly explained in the Note no. 19 of the Financial Statement.

2. Secretarial Auditors and their Report:

The members of Board has appointed M/s. Kavita Rathi, Practicing Company Secretary to conduct Secretarial Audit of the Company for the financial year 2023-2024 at their meeting on 24^th May, 2023 as required under Section 204 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

The report of the Secretarial Auditors in Form MR-3 is enclosed as Annexure-I to this report.

The report confirms that the Company had complied with the statutory provisions listed under Form MR -3 and the Company also has proper board processes and compliance mechanism.

The report does not contains qualifications, reservation or adverse remark for which further comments or explanations.

3. Internal Auditor:

The Members of Board has appointed M/s. Jain N K & Co., (FRN: 148125W) Chartered Accountant, as Internal Auditors of the Company for Financial Year 2023-2024 at their meeting on 24^th May, 2023 under provisions of Section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 as recommended by Audit Committee.

The Suggestions made by the Internal Auditor in their Report were properly implemented.

Human Resources

Human Resources Development envisages the growth of the individual in tandem with the organization. It also aims at the up-liftment of the individual by ensuring an enabling environment to develop capabilities and to optimize performance. Your Directors want to place on record their appreciation for the contribution made by employees at all levels, who through their steadfastness, solidarity and with their co-operation and support have made it possible for the Company to achieve its current status.

The Company, on its part, would endeavor to tap individual talents and through various initiatives, ingrain in our human resources, a sense of job satisfaction that would, with time, percolates down the line. It is also the endeavor of the Company to create in its employees a sense of belonging, and an environment that promotes openness, creativity and innovation.

All the manpower initiatives including training, meetings and brainstorming sessions are implemented with the aim of maximizing productivity and aligning organizational needs employees aspirations.

Listing of Securities

The Equity Shares of your Company is listed with The Calcutta Stock Exchange Limited (CSE). Listing fees has been paid to The Calcutta Stock Exchange Ltd. in pursuance to Regulation 14 of the Listing Regulation.

Shares

The Authorized Share capital and the paid up Equity Share Capital have remained unchanged during the year under review. The Company has neither issued shares & Securities or any other instruments nor any corporate benefits during the year under review.

1. The Company has not bought back any of its securities during the year under review. 2. The Company has not issued any Sweat Equity Shares during the year under review. 3. No Bonus Shares were issued during the year under review. 4. The Company has not provided any Stock Option Scheme to the employees.

Details of policy developed and implemented by the Company on its Corporate Social Responsibility Initiatives

Since the Company does not developed and implemented any Corporate Social Responsibility initiatives as the said provisions are not applicable to the Company.

Additional Information to Shareholders

All important and pertinent investor information such as financial results, investor presentations, press releases are made available on the Companys website i.e. www.mavensbiotech.com on a regular basis.

Code of Conduct

As prescribed under Listing Regulation, a declaration signed by the Companys Managing Director & Chief Executive Officer affirming compliance with the Code of Conduct by the Directors and Senior Management Personnel of the Company for the financial year 2023-2024 forms part of the Governance Report.

Secretarial standards

The Company complies with all applicable secretarial standards issued by the Institute of Company Secretaries of India.

Board Diversity Policy: -

In compliances with the provision of the Listing Regulations, 2015, the Board through its Nomination and Remuneration Committee has devised a Policy on Board Diversity.

The objective of the Policy is to ensure that the Board comprises adequate number of members with diverse experience and skills, experience, such that it best serves the governance and strategic needs of the Company leading to competitive advantage. The Board composition is mentioned in available in the Corporate Governance report that forms part of this Annual Report.

Familiarization Program:-

Whenever any person joins the Board of the Company as an Independent Director, an induction programme is arranged for the new appointee, wherein the appointee is familiarized with the Company, his/her roles, rights and responsibilities in the Company, the Code of Conduct of the Company to be adhered, nature of the industry in which the Company operates, and business model of the Company etc. The details of such familiarization programmes have been disclosed on the Company website i.e. https://www.mavensbiotech.com/Company%20Announcements/Company%20Announcements.html.

Reporting of Frauds

During the year under review, the Statutory Auditors and Secretarial Auditors have not reported to the Audit Committee and / or Board any instances of fraud committed in the Company by its officers or employees under Section 143(12) of the Companies Act, 2013.

Vigil Mechanism/ Whistle Blower Policy

Your company is committed to highest standards of ethical, moral and legal business conduct. Accordingly, the Board of Directors have formulated a Whistle Blower Policy which is in compliance with the provisions of Section 177(10) of the Companies Act, 2013 and Regulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The policy provides for a framework and process whereby concerns can be raised by its employees against any kind of discrimination, harassment, victimization or any other unfair practice being adopted against them. These have been outlined in the Corporate Governance Report which forms part of this report.

Disclosure under the Sexual Harassment of Woman at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013.

Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

The following is a summary of sexual harassment complaints received and disposed off during the year 2023-2024:

No of complaints received	Nil
No of complaints disposed off	Nil
No of complaints pending as on end of the financial year	Nil

Disclosures

3 Maintenance of cost records and requirement of cost Audit as prescribed under the provisions of Section 148(1) of the Act are not applicable to the business activities carried out by the Company.

3 The Company has not accepted any fixed deposits during the year under review and accordingly, no amount on account of principal or interest on deposits from public and/or Members were outstanding as at March 31, 2024.

3 During the year under review, the Company has not issued any Debentures.

3 There are no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and the Companys operations in future.

3 No material changes have taken place that could have an impact on the financial position of the Company from the date of closure of financial year under review till the date of signing of Accounts.

3 There is no proceeding initiated or pending against the company under the Insolvency and Bankruptcy Code, 2016

3 There is no change in the nature of business of the Company.

3 During the year under review, the Company has not required take Credit Rating of Securities from any agency.

3 During the year under review, the Company has not required transferred any shares in IEPF (Investors Education & Protection Fund).

3 During the year under review Company does not come under failure of implement any Corporate Action.

3 During the year under review, the Company has not required the Compliance of Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and is of the view that the same is not applicable to company as the Company has not issued any share by way of public issue, Right Issue, Preferential Issue etc.

Acknowledgement

The Directors wish to place on record their appreciation for the contributions made by the employees at all levels, whose continued commitment and dedication helped the Company achieve better results. The Directors also wish to thank customers, bankers, Central and State Governments for their continued support. Finally, your directors would like to express their sincere & whole-hearted gratitude to all of you for your faith in us and your Cooperation & never failing support.

	By Order of the Board
	For Mavens Biotech Limited
	Jay Prakash	Chanderkala Devi Lakhotia
	(Managing Director & CEO)	(Director)
	(DIN: 02525414)	(DIN: 06904489)
Regd. Office	Room No. 407, 4th Floor, PremisesNo.4,
	Clive Row Kolkata-700001
CIN	L17297WB1981PLC034226
Email	investors@mavensbiotech.com
Website	www.mavensbiotech.com
Date	26th June, 2024